Transcriptomic concentration-response evaluation of valproic acid, cyproconazole, and hexaconazole in the neural

Peter T Theunissen1, Joshua F Robinson, Jeroen L A Pennings

  • 1Laboratory for Health Protection Research, National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, The Netherlands. peter.theunissen@rivm.nl

Insights

This study enhances the embryonic stem cell test (ESTn) for developmental toxicity by incorporating transcriptomics. This approach provides earlier and more sensitive detection of chemical effects on neural development than traditional methods.

Area of Science:

  • Developmental Toxicology
  • Stem Cell Assays
  • Toxicogenomics

Background:

  • Regulatory developmental toxicology urgently requires alternatives to animal testing.
  • The in vitro murine neural embryonic stem cell test (ESTn) was previously developed for neurodevelopmental toxicity.
  • Integrating toxicogenomic approaches can improve ESTn predictivity and mechanistic understanding.

Purpose of the Study:

  • To investigate the concentration-dependent effects of known developmental toxicants on gene expression during neural differentiation using transcriptomics.
  • To assess the utility of incorporating transcriptomics into the ESTn for enhanced neurodevelopmental toxicity testing.
  • To gain mechanistic insights into the effects of cyproconazole, hexaconazole, and valproic acid.

Main Methods:

  • Utilized a transcriptomic approach to analyze gene expression changes in murine neural embryonic stem cells after exposure to cyproconazole, hexaconazole, and valproic acid.
  • Assessed concentration-dependent effects on gene expression and gene ontology (GO) terms after 24 hours of exposure.
  • Correlated transcriptomic findings with morphological changes observed on day 11 of culture.

Main Results:

  • All tested compounds (cyproconazole, hexaconazole, valproic acid) enriched the embryonic development process.
  • Cyproconazole and valproic acid significantly enriched the neuron development process, while hexaconazole did not.
  • Triazole compounds and valproic acid showed specific responses within the sterol metabolic process GO term.
  • Transcriptomics detected effects preceding morphological changes, offering a more sensitive measure of concentration-dependent toxicity compared to morphological assessments.

Conclusions:

  • Incorporating transcriptomics into the ESTn enhances its sensitivity and provides mechanistic insights for developmental toxicity assessment.
  • This approach allows for earlier detection of chemical-induced effects on neural development.
  • Mechanistic data from transcriptomics can aid in extrapolating in vitro findings to human hazard assessment.